





































On the Horizon From the ORS
Platelet-rich Blood Derivatives for Tendon
Regeneration
Abstract
Tendon injuries constitute a significant healthcare problem with
variable clinical outcomes. The complex interplay of tissue
homeostasis, degeneration, repair, and regeneration makes the
development of successful delivery therapeutic strategies
challenging. Platelet-rich hemoderivatives, a source of supra-
physiologic concentrations of human therapeutic factors, are a
promising application to treat tendon injuries from the perspective of
tendon tissue engineering, although the outcomes remain
controversial.
Tendon injuries are com-mon debilitating musculoskeletal
problems. More than 30 million ten-
don surgical procedures take place
annually worldwide, with an associ-
ated expenditure of more than €150
billion in the United States and
European Union.1-3 Healing tendons
display high re-rupture risk during the
first weeks after surgical repair.4
Hence, augmentation strategies hold
interesting potential to shift the injury
environment toward enhanced heal-
ing and ultimately to achieve tendon
repair and regeneration, particularly
for chronic tendinopathies.5,6 The
interplay between different bio-
molecules makes tissue homeostasis,
degeneration, repair, and regeneration
complex processes. The orchestration
of tendon healing is differentially
regulated when comparing fetal and
adult tissues,7-10 and it involves
numerous cytokines (eg, interleukin
[IL]-6, IL-1b) and growth factors
(GFs, eg, basic fibroblast GF, trans-
formingGF-b, insulin-like GF [IGF]-1,
platelet-derived GF, and bone mor-
phogenetic proteins-12, -13, and -14)
which are released in a temporally and
spatially controlled manner.11-13 Dif-
ferent strategies have been pursued for
delivering these biomolecules, includ-
ing gene therapy and local delivery of
GFs through injection or biomaterial
vehicles.11,14 Recently, the recognition
that several GFs come into play during
tendon healing contributed to the
investigation of concentrated collec-
tions of various GFs.
Platelet-rich
Hemoderivatives
The rationale for using platelet-rich
hemoderivatives (PRHds) stems from
the regulatory role of the cytokines
and GFs released from platelets on
activation during the healing process.
PRHdshave been explored asa source
of human therapeutic factors in both
autologous and allogeneic settings.15
Platelet-derived GF, transforming
GF-b, vascular endothelial GF, basic
fibroblast GF, epithelial GF, bone
morphogenetic proteins, platelet-
secreted GFs with relevance to tissue
regeneration are present in high levels
in PRHds.16 Other molecules with
therapeutic interest can be found in
high concentrations in PRHds,
namely, fibrinogen, a precursor of
fibrin clot,17 and immunomodulatory
cytokines (eg, IL-1, IL-4, IL-6, and
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tumor necrosis factor-a).16 More-
over, molecules with antimicrobial
properties or those involved in
humoral immunity can be found in
PRHds, namely, b-lysin, platelet
factor-4, or complement
proteins.18,19
The composition of different
PRHds, and thus their therapeutic
effect, greatly depends on the prepa-
ration protocol, activationmethod,20
and donor variability.21 PRHds are
usually obtained by centrifugation of
the peripheral whole blood (WB)
(Figure 1). On centrifugation, the
WB separates into two phases, which
clot spontaneously. The upper
phase, a yellowish clot rich in fibrin,
platelets, and leucocytes, Choukroun
and coworkers called platelet-rich
fibrin,23 has been proposed as an
autologous patch for regenerative
applications. However, if an ade-
quate anticlotting agent (usually
citrate or heparin) is added to the
WB, the upper phase can be collected
and submitted to further platelet
concentration protocols, such as
buffy coat or the PRP methods,
commercial kits,24 or apheresis,25,26
yielding platelet concentrate, also
termed platelet-rich plasma (PRP).
The platelet concentrate (or PRP)
can be used directly or as activated
(eg, with thrombin and/or calcium
salts27,28), producing a solid fibrin
clot, termed platelet gel, which
releases a solution of plasma rich in
GFs. The PRP produced from dif-
ferent protocols present significant
differences in platelet, leukocyte, and
fibrin content that translate in vari-
able clinical outcomes of the PRP-
based treatments24 and have raised
the need for standardization of PRP
preparation and nomenclature
(revised elsewhere20). Finally, the
platelet lysate (PL) is a liquid sus-
pension of fibrin and GFs in plasma
obtained by cryogenic25,26 or ultra-
sonic29 disruption of the platelets’





Outlook on Clinical Studies
PRP injection has been the most
explored application of PRHds for
treating tendinopathies reported in
in vivo studies.30-33 Local PRP injec-
tion in rat models of rotator cuff injury
prevented the acute inflammatory
response and scar tissue formation,
resulting in improved tendon healing,
through the formation of reparative
fibrous and granulation tissue, and
biomechanical performance.30,31 The
combination of PRP and biomaterials
has also been explored. Collagen
sponges impregnated with PRP and
harboring tendon stem cells delivery to
acute Achilles tendon repair rat model
resulted in increased collagen type I
gene expression as soon as 3 days after
treatment under loading conditions,
but no other differences were observed
regarding tissue morphology.32
Clinical studieshave shownmidterm
positive outcomes (improved activity
level, reduced pain) on multiple PRP
injections for the treatment of Achil-
les34 and rotator cuff35 tendinopathy
but without differences in tissue
integrity comparatively with the con-
trols. A meta-analysis of eight studies
comparing clinical outcomes of rota-
tor cuff repair with or without PRP
using the most commonly used clini-
cal score system (patient self-reported
outcome measures: Constant Score,
American Shoulder and Elbow Soci-
ety, University of California-Los
Figure 1
Schematic representation of the generic protocols for the production of platelet-
rich hemoderivatives and the targets of the clinical trials proposing their
applications in the management of tendinopathies. PC = platelet concentrate,
PRF = platelet-rich fibrin. (Adapted with permission from Mendes BB, Gómez-
Florit M, Babo PS, Domingues R, Reis RL, Gomes ME: Blood derivatives
awaken in regenerative medicine strategies to modulate wound healing. Adv
Drug Deliv Rev 2018;129:376-393 and Babo PS, Reis RL, Gomes ME:
Periodontal tissue engineering: Current strategies and the role of platelet rich
hemoderivatives. J Mater Chem B 2017;5:3617-3628.16)
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Angeles, Simple Shoulder Test, Visual
Analog Scale scores36) showed dif-
ferences in Constant Scores, Simple
Shoulder Test, and Visual Analog
Scale but no effect on the American
Shoulder and Elbow Society, Univer-
sity of California-Los Angeles, and re-
tear rates.37 A meta-analysis of eight
randomized clinical trials of PRP
compared with steroid on lateral ep-
icondylitis treatment reported that
PRP seems to be more effective in
reducing pain and improving elbow
function in the intermediate term
(12 weeks) and long term (half year
and 1 year).38 PRP administration
to the patellar tendon donor site in
anterior cruciate ligament recon-
struction procedures resulted in
improved donor site healing and
reduced pain after 6 months.39 The
clinical outcomes of the PRHds might
depend on several factors not
included in most scientific reports. For
instance, the leukocyte in PRP corre-
lates with the inflammatory response
in the recipient tissue, as observed
after injection of leukocyte-rich or
-poor PRP in healthy patellar tendon
rabbit models.33 PRP treatment effi-
cacy of Achilles tendinopathy has also
been reported to depend on patient’s
age,40 indicating that these prepara-
tions do not overcome the limited
tendon healing capacity in elderly
patients. Hence, patient’s age could
be a determinant factor to unravel the





Despite the inconsistent results in
terms of clinical translation,6 the use
of PRHds other than PRP in in vitro
settings has been gaining attention
to modulate cell behavior, particu-
larly for tendon tissue engineering.
Plasma rich in GF has been shown
to induce rabbit patellar tendon
stem cells differentiation toward a
tenocytic phenotype and to stimu-
late tenocytes derived from chronic
rotator cuff tendon tears, leading to
increased expression of tenogenic
genes and proteins in vitro.41,42
Additionally, PL-based patches
have also been reported to induce a
proregenerative state on tendon
cells through an upregulation of




Overall, a direct injection of PRP or
the activation of the coagulation
cascade pre-/postinjection (eg, use of
thrombin and/or calcium) is still the
preferred method in clinical scenar-
ios of the management of tendino-
pathies. Recently, other PRHds,
namely, platelet-rich fibrin and PL,
have also been proposed for clinical
trials aiming at the manage-
ment of rotator cuff tear44 (Clinical
Trials no. NCT01612845 and no.
NCT02256891) and lateral epi-
condylitis (Clinical Trial no.
NCT01668862), respectively (Fig-
ure 1). The contradictory results of
therapeutic studies, likely reflecting
the lack of consensus on PRHds
preparation protocols and nomen-
clature, as well as donor/patient
variability, limit PRHds translation
to clinic. A concerted effort is
needed to develop more predictable
PRHds-based therapies, by not only
addressing the above-listed issues
but also combining refined tendon
tissue engineering strategies, like
PRHds-based biomaterials or com-
posites,43,45,46 ultimately allowing
the fine modulation of the spatial,
temporal, and dosage release of the
adequate biochemical stimuli.46,47
This could ultimately shift applica-
tions from the injury environment
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